 CAMBRIDGE, Mass., April 01, 2022 GLOBE NEWSWIRE -- Synlogic, Inc. Nasdaq: SYBX, a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that data from its phenylketonuria PKU and homocystinuria HCU programs will be highlighted in two poster presentations at the Society for Inherited Metabolic Disorders SIMD 43rd Annual Meeting being held April 10-13, 2022 in Orlando, Florida. 